Updated: 5:00 p.m. March 20 Shares for Goleta-based breast implant developer Sientra fell 4.5 percent March 19 after the company received a warning letter from the U.S. Food and Drug Administration related to long-term studies of its products. The FDA said in the letter that Sientra had failed to comply with post-approval study requirements, including…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
